|
Toll Free: (877) 796-6397 -- USA and Canada only -- |
Fax: +1-832-582-8590 Orders: +1-832-582-8158 |
Tech Support: +1-832-582-8158 Ext:3 Please provide your Order Number in the email. |
Technical Data
| Formula | C30H34N8 |
|||
| Molecular Weight | 506.64 | CAS No. | 1037624-75-1 | |
| Solubility (25°C)* | In vitro | DMSO | 20 mg/mL warmed with 50ºC water bath (39.47 mM) | |
| Water | Insoluble | |||
| Ethanol | Insoluble | |||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.) |
||||
Preparing Stock Solutions
Biological Activity
| Description | Bemcentinib (R428, BGB324) is an inhibitor of Axl with IC50 of 14 nM, >100-fold selective for Axl versus Abl. Selectivty for Axl is also greater than Mer and Tyro3 (50-to-100- fold more selective) and InsR, EGFR, HER2, and PDGFRβ (100- fold more selective). | ||
|---|---|---|---|
| Targets |
|
||
| In vitro | R428 blocks the catalytic and procancerous activities of Axl. R428 inhibits Axl with low nanomolar activity and blocks Axl-dependent events, including Akt phosphorylation, breast cancer cell invasion, and proinflammatory cytokine production. [1] In a recent study, the Axl inhibitor R428 shows a mean IC50 dose of ∼ 2.0μM for the primary CLL B cells after 24 hours of treatment and normal B-, T-, and natural killer (NK) cells show no significant amount of cell death at this dose of R428 (2.5 μM) under similar experimental conditions. [2] | ||
| In vivo | Pharmacologic investigations reveal favorable exposure after oral administration such that R428-treated tumors display a dose-dependent reduction in expression of the cytokine granulocyte macrophage colony-stimulating factor and the epithelial-mesenchymal transition transcriptional regulator Snail. In support of an earlier study, R428 inhibits angiogenesis in corneal micropocket and tumor models. R428 administration reduces metastatic burden and extends survival in MDA-MB-231 intracardiac and 4T1 orthotopic (median survival, >80 days compared with 52 days; P < 0.05) mouse models of breast cancer metastasis. [1] |
Protocol (from reference)
| Animal Study: |
|
|---|
References
|
Customer Product Validation
-
Data from [Data independently produced by Cancer Res, 2014, 74(18), 5152-64]
-
Data from [Data independently produced by Biochem Bioph Res Co, 2014, 10.1016/j.bbrc.2014.10.126]
-
, , FASEB J, 2017, 31(4):1382-1397
-
Data from [Data independently produced by , , Blood, 2018, doi:10.1182/blood-2018-05-853291]
Selleck's Bemcentinib (R428) has been cited by 132 publications
| CD276-dependent efferocytosis by tumor-associated macrophages promotes immune evasion in bladder cancer [ Nat Commun, 2024, 15(1):2818] | PubMed: 38561369 |
| Directed differentiation of pancreatic δ cells from human pluripotent stem cells [ Nat Commun, 2024, 15(1):6344] | PubMed: 39068220 |
| AXL-specific single domain antibodies show diagnostic potential and anti-tumor activity in Acute Myeloid Leukemia [ Theranostics, 2024, 14(7):2656-2674] | PubMed: 38773967 |
| AXL-specific single domain antibodies show diagnostic potential and anti-tumor activity in Acute Myeloid Leukemia [ Theranostics, 2024, 14(7):2656-2674] | PubMed: 38773967 |
| Development of nanoparticles incorporated with quercetin and ACE2-membrane as a novel therapy for COVID-19 [ J Nanobiotechnology, 2024, 22(1):169] | PubMed: 38609998 |
| Novel therapeutic strategies targeting bypass pathways and mitochondrial dysfunction to combat resistance to RET inhibitors in NSCLC [ Biochim Biophys Acta Mol Basis Dis, 2024, 1870(6):167249] | PubMed: 38768929 |
| Atypical KCNQ1/Kv7 channel function in a neonatal diabetes patient: Hypersecretion preceded the failure of pancreatic β-cells [ iScience, 2024, 27(7):110291] | PubMed: 39055936 |
| Novel markers of MCL1 inhibitor sensitivity in triple-negative breast cancer cells [ J Biol Chem, 2024, 300(6):107375] | PubMed: 38762181 |
| Impact of sunitinib resistance on clear cell renal cell carcinoma therapeutic sensitivity in vitro [ Cell Cycle, 2024, 1-13.] | PubMed: 38263737 |
| MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC [ J Thorac Oncol, 2023, 10.1016/j.jtho.2023.10.017] | PubMed: 37924972 |
RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.
SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.
NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.